HCW Biologics Statistics
Want to see HCWB full AI Analyst Report?
HCW Biologics (HCWB) Stock Statistics & Valuation Metrics
Total Valuation
HCW Biologics has a market cap or net worth of $2.44M. The enterprise value is $9.47M.
- Market Cap
- $2.44M
- Enterprise Value
- $9.47M
Share Statistics
HCW Biologics has 3,139,938 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 3,139,938
- Owned by Insiders
- 7.43%
- Owned by Institutions
- 0.60%
Financial Efficiency
HCW Biologics’s return on equity (ROE) is -2.88 and return on invested capital (ROIC) is -109.65%.
- Return on Equity (ROE)
- -2.88
- Return on Assets (ROA)
- -0.32
- Return on Invested Capital (ROIC)
- -109.65%
- Return on Capital Employed (ROCE)
- -3.26
- Revenue Per Employee
- 1,549.486
- Profits Per Employee
- -227.42K
- Employee Count
- 35
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of HCW Biologics is -0.03. HCW Biologics’s PEG ratio is -0.00.
- PE Ratio
- -0.03
- PS Ratio
- 0.04
- PB Ratio
- 0.24
- Price to FCF
- -0.02
- Price to Operating Cash Flow
- -0.14
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, HCW Biologics had revenue of 54.23K and earned -7.96M in profits. Earnings per share was -63.78.
- Revenue
- 54.23K
- Gross Profit
- 10.85K
- Operating Income
- -11.26M
- Pretax Income
- -7.96M
- Net Income
- -7.96M
- EBITDA
- -5.67M
- Earnings Per Share (EPS)
- -63.78
Cash Flow
In the last 12 months, operating cash flow was -11.52M and capital expenditures -3, giving a free cash flow of -11.52M billion.
- Operating Cash Flow
- -11.52M
- Free Cash Flow
- -11.52M
- Free Cash Flow per Share
- -5.48
Dividends & Yields
HCW Biologics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -4129.44%
- Earnings Yield
- -212.89%
Stock Price Statistics
- Beta
- 2.74
- 52-Week Price Change
- -94.72%
- 50-Day Moving Average
- 1.48
- 200-Day Moving Average
- 3.74
- Relative Strength Index (RSI)
- 23.75
- Average Volume (3m)
- 381.56K
Important Dates
HCW Biologics upcoming earnings date is Mar 31, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 16, 2026
- Next Earnings Date
- Mar 31, 2027
- Ex-Dividend Date
- ―
Financial Position
HCW Biologics as a current ratio of 0.11, with Debt / Equity ratio of 246.29%
- Current Ratio
- 0.11
- Quick Ratio
- 0.11
- Debt to Market Cap
- 3.35
- Net Debt to EBITDA
- -0.86
- Interest Coverage Ratio
- -9.00
Taxes
In the past 12 months, HCW Biologics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
HCW Biologics EV to EBITDA ratio is -2.06, with an EV/FCF ratio of -0.53.
- EV to Sales
- 0.91
- EV to EBITDA
- -2.06
- EV to Free Cash Flow
- -0.53
- EV to Operating Cash Flow
- -0.53
Balance Sheet
HCW Biologics has $955.46K in cash and marketable securities with $6.83M in debt, giving a net cash position of -$5.88M billion.
- Cash & Marketable Securities
- $955.46K
- Total Debt
- $6.83M
- Net Cash
- -$5.88M
- Net Cash Per Share
- -$1.87
- Tangible Book Value Per Share
- $3.25
Margins
Gross margin is 95.72%, with operating margin of -80.87%, and net profit margin of -53.10%.
- Gross Margin
- 95.72%
- Operating Margin
- -80.87%
- Pretax Margin
- -57.70%
- Net Profit Margin
- -53.10%
- EBITDA Margin
- -44.30%
- EBIT Margin
- -52.38%
Analyst Forecast
The average price target for HCW Biologics is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $8.00
- Price Target Upside
- 948.49% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- 1502.05%
- EPS Growth Forecast
- 77.12%
Scores
- Smart Score
- ―
- AI Score
- 41

